Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Immunovant (IMVT) Interest & Investment Income (2019 - 2026)

Immunovant filings provide 4 years of Interest & Investment Income readings, the most recent being $5.3 million for Q4 2025.

  • Quarterly Interest & Investment Income rose 16.19% to $5.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.2 million through Dec 2025, down 7.86% year-over-year, with the annual reading at $24.7 million for FY2025, 0.87% down from the prior year.
  • Interest & Investment Income hit $5.3 million in Q4 2025 for Immunovant, down from $5.6 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $8.9 million in Q4 2023 and bottomed at $3.6 million in Q3 2023.
  • Average Interest & Investment Income over 3 years is $6.1 million, with a median of $6.1 million recorded in 2024.
  • Peak annual rise in Interest & Investment Income hit 76.63% in 2024, while the deepest fall reached 48.62% in 2024.
  • Immunovant's Interest & Investment Income stood at $8.9 million in 2023, then crashed by 48.62% to $4.6 million in 2024, then rose by 16.19% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Interest & Investment Income are $5.3 million (Q4 2025), $5.6 million (Q3 2025), and $6.3 million (Q2 2025).